Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
Blepharoptosis, Synkinesis, Hyperkinesis
About this trial
This is an interventional treatment trial for Blepharoptosis focused on measuring acquired blepharoptosis, hyperkinesis, synkinesis, facial paralysis, aberrant regeneration syndrome, post-paralysis synkinesis, nonflaccid facial paralysis
Eligibility Criteria
Inclusion Criteria: Over 18 years of age Primary diagnosis of nonflaccid facial paralysis (aberrant regeneration syndrome) and acquired blepharoptosis. Exclusion Criteria: Patients under the age of 18 Patients on cardiac glycosides Patients on MAO inhibitors Patients with angle closure glaucoma Patients who experience asymmetrical eye opening due to weakness (e.g. lagophthalmos).
Sites / Locations
- M.S. Hershey Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Oxymetazoline 0.1% ophthalmic drops
Preservative free lubricating drops
Patients will use once daily in affected eye. Drops are provided in single use vials.
Patients will use once daily in affected eye. Drops are provided in single use vials.